![]() ![]() Securities Act of 1933, as amended (the “U.S. The securities of Sonova have not been and will not be registered under the U.S. Over 17,000 employees are working on achieving Sonova’s vision of a world where everyone enjoys the delight of hearing.įor more information please visit Sonova shares (ticker symbol: SOON, Security no: 1254978, ISIN: CH0012549785) have been listed on the SIX Swiss Exchange since 1994. In the 2022/23 financial year, the Group generated sales of CHF 3.7 billion, with a net profit of CHF 658 million. The Group’s globally diversified sales and distribution channels serve an ever growing consumer base in more than 100 countries. Sonova operates through four businesses – Hearing Instruments, Audiological Care, Consumer Hearing and Cochlear Implants – and the core brands Phonak, Unitron, AudioNova, Sennheiser (under license) and Advanced Bionics as well as recognized regional brands. The Group was founded in 1947 and is headquartered in Stäfa, Switzerland. Sonova is a global leader in innovative hearing care solutions: from personal audio devices and wireless communication systems to audiological care services, hearing aids and cochlear implants. The succession plan that we have established provides the time and support to help Gilbert prepare diligently for his future role.” I am convinced that with his broad international experience, his deep understanding of the MedTech industry, his successful track record as CEO, and his long-standing work as Chair of the Board of Directors at various companies, he will be able to contribute significantly to the future growth of Sonova. Robert Spoerry, Chair of the Board of Directors of Sonova Holding AG, stated: “I am very pleased that the Board of Directors has found in Gilbert a candidate ideally suited to succeed me as Chair when I retire at the 2025 AGM. Gallen, Switzerland, and completed the Executive MBA program at the IMD in Lausanne, Switzerland. Achermann holds a degree in Business Administration from the University of Applied Science in St. He has also served since 2012 on the Board of Directors of Julius Baer Group, from which he will step down in 2024. Achermann became a member, and in 2022 the Chair, of the Board of Directors of Ypsomed Group, a manufacturer of injection and infusion systems. Prior to this, he served highly successfully as the Straumann Group’s CFO and later CEO for over 12 years. ![]() Having held this position since 2010, he will step down at the Straumann Group AGM in April 2024. Gilbert Achermann (born in 1964, Swiss citizen) currently serves as Chair of the Board of Directors of the Straumann Group, a global leader in the dental industry. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |